New insights into aging skin
Background
Traditional skin biopsy methods are invasive, requiring local anesthetic and sutures, which often leave scars. Recognizing the need for a less invasive alternative, Professor Tarl Prow developed a novel microbiopsy technique offering rapid, suture-free, sub-millimeter skin sampling, enhancing both the patient experience and healthcare outcomes.
Objective
To commercialize microbiopsy technology by transforming laboratory techniques into a practical, user-friendly product for dermatologists and cosmetics companies worldwide.
Approach
Leveraging deep expertise in commercialization and industry partnerships, we:
- bridged the gap between academic innovation and commercial scalability
- worked with a leading cosmetics company to use microbiopsy for profiling skin biomarkers related to aging, aligning the tool with industry needs
- addressed challenges such as global regulatory compliance, product usability and technology transfer.
Results
- Successful demonstration of the microbiopsy tool as a minimally invasive alternative to traditional biopsies, improving the patient experience and expanding sampling capabilities across geographic boundaries.
- Partnership with leading cosmetic companies in the application of microbiopsy in skin biomarker profiling, advancing research on aging and potential future skincare solutions.
- Translation of the technology into a scalable, user-friendly product that meets the needs of dermatologists and cosmetic companies globally.
Key takeaways
- We have enabled the successful commercialization of microbiopsy technology, ensuring it is both scientifically robust and market-ready.
- Collaboration with leading cosmetic companies demonstrated the versatility of microbiopsy in both clinical and cosmetic applications.
- By addressing practical challenges such as scalability and regulatory compliance, we helped bring a transformative sampling tool to market.
